Recruiting

Observational Study

Sponsor:

HealthTree Foundation

Code:

NCT04727294

Conditions

Multiple Myeloma

Smoldering Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance

Coronavirus

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Questionnaire

Study Details

Brief summary:

The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus.

The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.

This questionnaire is a follow-on to the "MM and COVID-19" questionnaire.

Conditions

Multiple Myeloma

Smoldering Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance

Coronavirus

Study ID

NCT04727294

Start date

Jan 22, 2021

Status verified date

Aug, 2021

Completion date

Dec, 2021

Anticipated

Primary completion date

Sep, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult patients (greater than 18 years) diagnosed with MGUS, smoldering myeloma, and multiple myeloma.
  • Access to a computer or electronic device with internet access, or phone
  • Willing to create a patient profile on the HealthTree Cure Hub For Multiple Myeloma
  • Willing to give electronically-signed consent
  • Ability to read questions in English

Study Design

Enrollment

1500 participants

Anticipated

Interventions and Outcome Measures

Arms

MGUS, SMM, MM Patients or their Caregivers

Eligible participants will be asked to create a free patient profile on the HealthTree Cure Hub (www.healthtree.org) or use their existing patient profile.

The creation of a HealthTree Cure Hub patient profile will serve as a screen for eligibility.

Patients will complete a one-time questionnaire found on the HealthTree Cure Hub. Telephone assistance can be provided as needed. The questionnaire will take 20-30 minutes to complete.

Interventions

Questionnaire

Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.

Primary outcome measure

  • COVID-19 Diagnosis and Treatment [ Time Frame: Up to one year ]
  • Changes to Myeloma Treatment and Care [ Time Frame: Up to one year ]
  • Health and Fitness [ Time Frame: Up to one year ]
  • Quality of Life (QOL) Distress Screening tool [ Time Frame: Up to one year ]

Central Contacts and Locations

Central contacts

Nathan Sweeney, PhD

18007091113nathan@healthtree.org

Locations

HealthTree.org (Online)

Recruiting

Lehi, Utah, United States, 84043

Contacts

Nathan Sweeney, PhD

800-709-1113nathan@healthtree.org

Ana Sahagun, MS

1-800-709-1113

More Information

Sponsor

HealthTree Foundation

Last update posted

Aug 4, 2021

Last verified

Aug, 2021

Keywords

  • Questionnaire

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by HealthTree Foundation on 2021-08-04.